Freenome, Inc. (FRNM) · Oct 20, 2026 · Other events

Freenome launches lung test, but FDA review remains ahead

SimpleScreen Lung launch — 85% sensitivity, 50% specificity, 99.8% NPV

Freenome’s lung cancer test is now available as an LDT, adding a one-draw CRC combo—but regulatory clearance and commercial uptake remain ahead.

Freenome is moving from a newly commercialized CRC test into a broader blood-based cancer-screening portfolio: SimpleScreen CRC received FDA approval in July 2026 and is being commercialized in the U.S. by Abbott, while SimpleScreen Lung had already received FDA Breakthrough Device designation in August. This filing turns that pipeline direction into an actual lung-test launch. Freenome says SimpleScreen Lung can be ordered alone or alongside SimpleScreen CRC, creating a practical two-cancer screening workflow from one blood draw. 〔0〕

The validation supports the product story, but does not yet establish a regulatory or commercial win. In an independent cohort of 172 lung-cancer cases and 436 controls, the test delivered 85% sensitivity, 50% specificity and a 99.8% negative predictive value. 〔1〕 The low 50% specificity means half of people without lung cancer could test positive and require follow-up, while the study is materially smaller and less definitive than the more than 48,000-participant prospective CRC study underpinning the existing product. 〔2〕

The key limitation is that SimpleScreen Lung is launching before FDA clearance. The company explicitly says the test is a laboratory-developed test and “has not been reviewed or cleared/approved by the U.S. Food and Drug Administration (FDA).” 〔3〕 That makes this a commercial-access and adoption step—not yet the regulatory validation that would broaden the addressable market or remove questions around clinical use.

The one-draw combination strengthens Freenome’s portfolio strategy, but execution is now the test. The offering is directionally consistent with the company’s previously disclosed Personalized Cancer Detection strategy and the expected expansion beyond CRC, so the surprise is the launch and the accompanying performance details rather than the concept itself. Freenome now has to demonstrate that providers will add an unapproved lung LDT to visits already used for CRC screening, while Abbott handles standalone CRC commercialization.

Bottom line: This advances Freenome from a one-product CRC story toward a multi-cancer screening platform, making it a meaningful operational step. The signal is modestly positive, but the lung product remains an early commercial experiment pending regulatory progress and real-world adoption.

What to watch next

Q3 2026 results, November 10

Original filing on SEC EDGAR

Freenome launches lung test, but FDA review remains ahead | FRNM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.